Financial Performance - Q2 2025 - Revenue reached $428 million[5], a 3% decrease year-over-year[21, 45] - Organic revenue grew by 5% year-over-year[21, 45] - Adjusted EBITDA was $105 million[5], a 12% decrease year-over-year[21] - Unlevered Free Cash Flow (uFCF) was $53.869 million[54] - Adjusted net income was $0.46 million[5] Segment Performance - Merchant Solutions revenue was $232.2 million[39] - Digital Wallets revenue was $201.2 million[39] - Merchant Solutions organic revenue growth was 6%[25, 47] - Digital Wallets volume increased by 15%[26] Financial Position - The company has a net leverage ratio of 5.4x[5] - Total debt is $2.551 billion[27] - Net debt is $2.285 billion[27] - Available liquidity is $414 million[27]

Financial Results for the Quarter Ended June 30, 2025 MidCap Financial Investment Corporation August 11, 2025 Unless otherwise noted, information as of June 30, 2025. Confidential and Proprietary - Not for distribution, in whole or in part, without the express written consent of Apollo Global Management, Inc. It should not be assumed that investments made in the future will be profitable or will equal the performance of the investments shown in this document. Disclaimers, Definitions and Important Notes For ...

Financial Performance & Guidance - Q3 2025 revenue reached $603 million[12], while adjusted EBITDA was $27 million[12] - The company reaffirmed its FY25 adjusted EBITDA guidance of $0-$20 million[12] - The company expects to be at the bottom end of the revenue guidance range of $2.6 billion[12] primarily due to slower US production ramp - The company delivered a 15.4% adjusted gross profit margin in Q3 2025[35] - The company has approximately $460 million in total cash as of June 30, 2025[12] Backlog & Pipeline - The company has approximately $4.9 billion in backlog as of June 30, 2025[12] - The company's pipeline is approximately $23.5 billion as of June 30, 2025[12] - $2.5 billion of FY'26 revenue is now secured in backlog[12] OBBBA & Tariffs - The Inflation Reduction Act (IRA) extends Section 48E ITC for storage through 2034, providing long-term security[16] - The IRA incentivizes an additional 10% ITC if minimum domestic content thresholds are met[16] - The company is working with domestic suppliers to ensure compliance with the OBBBA by the end of the year[19] - The total tariff on Chinese batteries in calendar year 2025 is projected to be 40.9%, and 58.4% in 2026[21] Market & Strategy - Two Australia contracts totaling approximately $700 million were added to the backlog[11] - Battery storage is now more cost-effective than gas, driving increased data center opportunities[44]

Nasdaq: ARQ Q2 2025 Earnings Call August 12, 2025 Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and 21E of the Securities Exchange Act of 1934, as amended, which provides a "safe harbor" for such statements in certain circumstances. When used in this presentation, the words "anticipates," "may," "believes," "expects," "intends," "plans," "estimates," "predicts," the negative expressions of such words, or similar ...

Financial Performance - Net revenue increased by 29% YoY to R$5635 million, excluding non-recurring effects, construction, and financial asset bifurcation[15, 17] - Adjusted EBITDA increased by 215% YoY to R$3617 million, excluding non-recurring effects, construction, and financial asset bifurcation[15, 19] - Net income increased significantly by 766% YoY to R$2136 million[15, 43] - Cash flow from operations increased by 794% YoY to R$3181 million[15] - Cash conversion rate improved from 595% to 879%[15] Operational Highlights - Water production volume increased by 48% YoY[10] - Water connections increased by 08% YoY[12] - Sewage connections increased by 11% YoY[13] Revenue Analysis - FAUSP price contributed R$290 million to revenue[23] - Volume contributed R$210 million to revenue[23] - Mix impact reduced revenue by R$138 million, mainly due to subsidized tariffs[23, 31] Cost Management - Personnel expenses decreased by R$77 million, a 103% reduction YoY, due to an 11% reduction in employee numbers[34, 39] - Energy expenses decreased by 37% YoY[34] Capex and Debt - Capex reached R$36 billion in 2Q25[79] - Debt issued in July 2025 included R$11 billion in Eco Invest 2032, R$10 billion in Eco Invest 2035, and R$28 billion in Blue Bond 2030[62] - Cash position as of July 2025 was R$129 billion[64] Key Ratios - Return on Invested Capital (ROIC) increased to 15%[66] - Return on Equity (ROE) increased to 13%[66]

August 12, 2025 Second Quarter 2025 Financial Results Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Jeffrey Creech Executive Vice President & Chief Financial Officer Mick McCloskey Vice President, Treasury & Investor Relations To participate via phone, please dial: 1-201-689-8345 4 2 Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private S ...

Second Quarter Earnings Presentation August 2025 Important notice Cautionary Note Regarding Forward-Looking Statements and Projections. Certain statements in this presentation may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, each as amended. Forward-looking statements provide current expectations of future events and include any statement th ...

Financial Performance - Q4 FY25 - Revenue remained flat at $60.159 billion[9] - Gross margin increased by 17% to $2.202 billion[9] - Operating earnings increased by 7% to $428 million on a GAAP basis and 19% to $719 million on a non-GAAP basis[9] - Net earnings increased by 2% to $239 million on a GAAP basis and 11% to $501 million on a non-GAAP basis[9] - Diluted EPS increased by 4% to $1.00 on a GAAP basis and 13% to $2.08 on a non-GAAP basis[9] Segment Performance - Q4 FY25 - Pharmaceutical and Specialty Solutions revenue decreased by 0% to $55.372 billion, while segment profit increased by 11% to $535 million[11] - Global Medical Products and Distribution revenue increased by 3% to $3.199 billion, and segment profit increased significantly by 49% to $70 million[15] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 37% to $1.609 billion, with segment profit increasing by 44% to $160 million[20] Financial Performance - FY25 - Revenue decreased by 2% to $222.578 billion[28] - Gross margin increased by 10% to $8.168 billion[28] - Operating earnings increased significantly by 83% to $2.275 billion on a GAAP basis and 15% to $2.786 billion on a non-GAAP basis[28] - Net earnings increased significantly by 83% to $1.561 billion on a GAAP basis and 7% to $1.995 billion on a non-GAAP basis[28] - Diluted EPS increased significantly by 87% to $6.45 on a GAAP basis and 9% to $8.24 on a non-GAAP basis[28] Segment Performance - FY25 - Pharmaceutical and Specialty Solutions revenue decreased by 3% to $204.644 billion, but segment profit increased by 12% to $2.258 billion[30] - Global Medical Products and Distribution revenue increased by 2% to $12.636 billion, with segment profit increasing significantly by 47% to $135 million[35] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 19% to $5.382 billion, and segment profit increased by 22% to $516 million[40] FY26 Outlook - Non-GAAP EPS is expected to be in the range of $9.30 - $9.50, revised from the previous outlook of $9.10 to $9.30[48] - Interest and Other expenses are projected to be approximately $275 million[48] - Non-GAAP adjusted free cash flow is expected to be between $2.75 billion and $3.25 billion[48]

Q2 2025 Key Performance Highlights - Funded Accounts reached 363 million, a 14% year-over-year increase[12] - Assets Under Administration (AUA) totaled $175 billion, up 54% year-over-year[12] - Net Contribution amounted to $210 million, reflecting a 26% year-over-year growth[12] - Adjusted EBITDA was $72 million, a 31% increase compared to the previous year[12] Business Strategy and Product Updates - The company is focused on four strategic pillars: Trading, Investing, Wealth Management, and Neo-Banking, to drive global expansion and product localization[15, 16, 17, 18, 19] - New product launches include 24/5 trading for U S equities and futures, new Smart Portfolios with Franklin Templeton, French savings products, and the eToro Card now available in multiple E U markets[22, 23, 26, 27] - The company is expanding its crypto offering in the U S, providing access to over 100 tokens[28] - The company launched Tori, an AI analyst providing personalized investment insights[29] Financial Performance Details - Net Trading Contribution from Equities, Commodities, and Currencies was $114042 thousand for the three months ended June 30, 2025[123] - Revenue from Cryptoassets was $1914792 thousand for the three months ended June 30, 2025[123] - Net income for Q2 2025 was $30185 thousand, which includes $15 million of IPO and other related costs[110, 130]

Liquidia Corporation 2Q2025 Financial Results & Corporate Update August 12, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 3 Rapid adoption over last 11 weeks! As of August 8, 2025 This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements ...